ZITUVIO
GrowthSMsitagliptin
NDAORALTABLET
Approved
Oct 2023
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
20
Mechanism of Action
Dipeptidyl Peptidase 4 Inhibitors
Pharmacologic Class:
Dipeptidyl Peptidase 4 Inhibitor
Clinical Trials (5)
Semaglutide vs Sitagliptin
Started Oct 2022
140 enrolled
Liver Transplant; ComplicationsDiabetes MellitusNASH - Nonalcoholic Steatohepatitis+1 more
Phase 1 Bioequivalence Study of Dapagliflozin/Sitagliptin FDC vs Loose Combination of Single Components
Started Mar 2022
46 enrolled
Healthy Volunteers (Intended Indication: Type 2 Diabetes Mellitus)
A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes
Started Jul 2019
1,441 enrolled
Diabetes Mellitus, Type 2
Drug Interaction Study Between Dorzagliatin and Sitagliptin
Started Jan 2019
15 enrolled
Patients
Sitagliptin and the Risk for Hypoglycaemia in Type 2 Diabetes Patients
Started Mar 2018
20 enrolled
Pharmacological Action
Loss of Exclusivity
LOE Date
Feb 25, 2035
109 months away
Patent Expiry
Feb 25, 2035
Patent Records (1)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 10925871 | Feb 25, 2035 | Product | — |